Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCDA NASDAQ:MYNZ NASDAQ:PTIX NASDAQ:SBFM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$1.34-3.6%$1.74$1.00▼$3.20$7.78M0.8304,899 shs190,745 shsMYNZMainz Biomed$1.60+5.3%$1.62$1.28▼$14.39$8.66M0.25210,935 shs507,858 shsPTIXAtrinsic$3.35-3.2%$3.39$2.25▼$15.26$1.97M0.381.61 million shs162,650 shsSBFMSunshine Biopharma$1.55-7.2%$1.47$1.17▼$3.90$7.07M1.48526,817 shs76,574 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia-2.11%+2.96%-34.12%-41.84%-48.13%MYNZMainz Biomed-5.00%-7.32%-8.43%-20.83%-89.90%PTIXAtrinsic+1.17%+4.85%+20.98%-6.23%-56.41%SBFMSunshine Biopharma-0.60%+10.59%+17.61%+8.44%-44.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCDABioCardia$1.34-3.6%$1.74$1.00▼$3.20$7.78M0.8304,899 shs190,745 shsMYNZMainz Biomed$1.60+5.3%$1.62$1.28▼$14.39$8.66M0.25210,935 shs507,858 shsPTIXAtrinsic$3.35-3.2%$3.39$2.25▼$15.26$1.97M0.381.61 million shs162,650 shsSBFMSunshine Biopharma$1.55-7.2%$1.47$1.17▼$3.90$7.07M1.48526,817 shs76,574 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCDABioCardia-2.11%+2.96%-34.12%-41.84%-48.13%MYNZMainz Biomed-5.00%-7.32%-8.43%-20.83%-89.90%PTIXAtrinsic+1.17%+4.85%+20.98%-6.23%-56.41%SBFMSunshine Biopharma-0.60%+10.59%+17.61%+8.44%-44.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCDABioCardia 2.50Moderate Buy$25.001,765.67% UpsideMYNZMainz Biomed 2.00Hold$14.00775.00% UpsidePTIXAtrinsic 0.00N/AN/AN/ASBFMSunshine Biopharma 2.00Hold$7.00351.61% UpsideCurrent Analyst Ratings BreakdownLatest PTIX, MYNZ, BCDA, and SBFM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025BCDABioCardiaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SBFMSunshine BiopharmaAegisSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.0010/8/2025SBFMSunshine BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BCDABioCardiaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025MYNZMainz BiomedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SBFMSunshine BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/23/2025BCDABioCardiaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/22/2025BCDABioCardiaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCDABioCardiaN/AN/AN/AN/A$0.18 per shareN/AMYNZMainz Biomed$890K9.73N/AN/A$2.61 per share0.61PTIXAtrinsicN/AN/AN/AN/A$1.96 per shareN/ASBFMSunshine Biopharma$34.87M0.20N/AN/A$9.10 per share0.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCDABioCardia-$7.95M-$1.85N/AN/AN/AN/A-19,117.42%-246.92%11/12/2025 (Estimated)MYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/APTIXAtrinsic-$5.53M-$9.44N/A∞N/AN/A-1,586.63%-585.65%N/ASBFMSunshine Biopharma-$5.13M-$150.88N/A∞N/A-17.35%-26.04%-20.72%11/4/2025 (Estimated)Latest PTIX, MYNZ, BCDA, and SBFM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/10/2025Q2 2025PTIXAtrinsicN/A-$1.37N/A-$1.37N/AN/A8/12/2025Q2 2025SBFMSunshine Biopharma-$0.11-$0.39-$0.28-$0.39$12.10 million$9.41 million8/11/2025Q2 2025BCDABioCardia-$0.50-$0.40+$0.10-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCDABioCardiaN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/APTIXAtrinsicN/AN/AN/AN/AN/ASBFMSunshine BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCDABioCardiaN/A0.330.33MYNZMainz Biomed0.440.520.43PTIXAtrinsicN/A0.860.86SBFMSunshine BiopharmaN/A5.002.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCDABioCardia20.57%MYNZMainz BiomedN/APTIXAtrinsic7.97%SBFMSunshine Biopharma41.98%Insider OwnershipCompanyInsider OwnershipBCDABioCardia20.00%MYNZMainz Biomed18.20%PTIXAtrinsic35.00%SBFMSunshine Biopharma0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCDABioCardia405.81 million4.65 millionOptionableMYNZMainz Biomed305.41 million4.43 millionNot OptionablePTIXAtrinsic2589,000383,000Not OptionableSBFMSunshine Biopharma34.56 million4.55 millionNot OptionablePTIX, MYNZ, BCDA, and SBFM HeadlinesRecent News About These CompaniesSunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus InfectionsOctober 9 at 8:00 AM | accessnewswire.comASunshine Biopharma's (SBFM) Sell (E+) Rating Reaffirmed at Weiss RatingsOctober 9 at 2:13 AM | americanbankingnews.comSunshine Biopharma Launches NIOPEG (R) Into $10 Billion Biologics Market - MorningstarJuly 3, 2025 | morningstar.comMSBFM - Sunshine Biopharma Inc News - MorningstarJuly 3, 2025 | morningstar.comMSunshine Biopharma, Inc. (SBFM) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comSunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics MarketJuly 2, 2025 | accessnewswire.comASunshine Biopharma Unit Launches Generic Anticonvulsant In Canada: Retail Sees ‘Huge Potential’June 11, 2025 | msn.comSunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion MarketJune 11, 2025 | accessnewswire.comASunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last YearMay 15, 2025 | accessnewswire.comASunshine Biopharma Inc.: Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion MarketMay 6, 2025 | finanznachrichten.deSunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion MarketMay 6, 2025 | accessnewswire.comASunshine Biopharma launches Everolimus in CanadaApril 22, 2025 | markets.businessinsider.comSunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 BillionApril 21, 2025 | accessnewswire.comASunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct OfferingApril 3, 2025 | accessnewswire.comAThis Pharma Stock Is Gaining Major Steam Ahead Of Opening BellApril 2, 2025 | msn.comSunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq RulesApril 2, 2025 | accessnewswire.comASunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer DrugApril 2, 2025 | benzinga.comSunshine Biopharma Announces Positive Results of mRNA Therapy for CancerApril 2, 2025 | finance.yahoo.comSunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last YearApril 1, 2025 | accessnewswire.comASunshine Biopharma signs agreement for rights to market two generic antibioticsMarch 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTIX, MYNZ, BCDA, and SBFM Company DescriptionsBioCardia NASDAQ:BCDA$1.34 -0.05 (-3.60%) Closing price 04:00 PM EasternExtended Trading$1.34 -0.01 (-0.37%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.Mainz Biomed NASDAQ:MYNZ$1.60 +0.08 (+5.26%) Closing price 04:00 PM EasternExtended Trading$1.60 -0.01 (-0.31%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.Atrinsic NASDAQ:PTIX$3.35 -0.11 (-3.18%) Closing price 04:00 PM EasternExtended Trading$3.26 -0.10 (-2.84%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.Sunshine Biopharma NASDAQ:SBFM$1.55 -0.12 (-7.19%) Closing price 04:00 PM EasternExtended Trading$1.53 -0.02 (-1.29%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
